(Albany, New York) – October 27, 2026 – The market dynamics for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA-associated Vasculitis) are witnessing steady growth driven by the rising prevalence of autoimmune vasculitis, increasing demand for effective disease management, and growing adoption of targeted therapies. Additionally, the development of emerging therapies such as depemokimab (GSK), benralizumab (AstraZeneca), BDB-001 (Staidson Biopharmaceuticals), iptacopan (Novartis), NM8074 (NovelMed Therapeutics), and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its latest report, “DelveInsight’s ANCA Vasculitis Market Insights, Epidemiology, and Market Forecast – 2036.” This comprehensive report provides an in-depth understanding of ANCA-associated Vasculitis, including historical and forecasted epidemiology, market trends, and treatment scenarios across the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
Key Takeaways from the ANCA-associated Vasculitis Market
- The ANCA-associated Vasculitis market across the seven major markets (7MM) is projected to grow from approximately USD 1.8 billion in 2025 to nearly USD 3.8 billion by 2036, registering a CAGR of approximately 6.5% during 2026–2036.
- The United States accounted for the highest number of diagnosed prevalent cases of ANCA-associated Vasculitis among the 7MM in 2025.
- According to DelveInsight’s estimates, there were approximately 226,000 diagnosed prevalent cases of ANCA-associated Vasculitis across the 7MM in 2025, with the United States accounting for the highest share.
- In 2025, Germany accounted for the largest number of diagnosed prevalent cases of ANCA-associated Vasculitis among the EU4 countries, followed by Italy, while Spain accounted for the lowest number of cases.
- In Japan, microscopic polyangiitis (MPA) accounted for the highest number of diagnosed prevalent cases among the three major ANCA-associated Vasculitis types, followed by granulomatosis with polyangiitis (GPA) and eosinophilic granulomatosis with polyangiitis (EGPA).
- Leading ANCA-associated Vasculitis companies, such as GlaxoSmithKline, CSL, Amgen, NS Pharma, Novartis, NovelMed Therapeutics, and others, are developing new treatment options.
- Promising therapies include avacopan (TAVNEOS), depemokimab, benralizumab (FASENRA), BDB-001, iptacopan, NM8074, sparsentan, povetacicept, and others.
Keen to know more about the market? Request our sample page athttps://www.delveinsight.com/sample-request/anti-neutrophil-cytoplasmic-antibody-associated-vasculitis-market
Key Factors Driving the ANCA-associated Vasculitis Market
Rising Disease Prevalence and Diagnosis Rates: ANCA-associated Vasculitis comprises a group of rare autoimmune disorders that cause inflammation of small blood vessels and can affect multiple organs, including the kidneys, lungs, skin, and nervous system. Improved disease awareness, diagnostic testing, and recognition of different clinical manifestations are contributing to earlier identification and treatment demand.
Increasing Demand for Targeted and Effective Therapies: Treatment generally involves remission induction and maintenance using glucocorticoids, immunosuppressants, and targeted therapies. The availability of treatments such as rituximab and avacopan has expanded management options, while ongoing research aims to improve disease control and reduce treatment-related toxicity.
Advancements in Biologics and Novel Immunomodulatory Approaches: Emerging therapies targeting eosinophils, complement pathways, and immune regulation are creating new opportunities in the ANCA-associated Vasculitis market. These approaches aim to improve remission rates, reduce relapses, and address unmet needs among patients with refractory or relapsing disease.
ANCA-associated Vasculitis Competitive Landscape
Several marketed and emerging therapies are shaping the ANCA-associated Vasculitis treatment landscape, including avacopan (TAVNEOS) (Amgen/ChemoCentryx), mepolizumab (NUCALA) (GlaxoSmithKline), benralizumab (FASENRA) (AstraZeneca), depemokimab (GlaxoSmithKline), BDB-001 (Staidson Biopharmaceuticals), iptacopan (Novartis), and NM8074 (NovelMed Therapeutics).
These therapies target different disease mechanisms. Avacopan inhibits the complement C5a receptor to reduce inflammatory activity, while mepolizumab and benralizumab target the interleukin-5 pathway or its receptor, particularly relevant to EGPA. Other investigational approaches focus on complement inhibition and immune modulation, with the aim of improving disease control, reducing glucocorticoid exposure, and addressing unmet treatment needs.
Discover more about therapies set to grab major ANCA-associated Vasculitis market share @ ANCA-associated Vasculitis Treatment Landscape
Recent Developments in the ANCA-associated Vasculitis Market
2025: DelveInsight’s market analysis highlighted the growing role of targeted therapies and emerging biologics in the treatment of ANCA-associated Vasculitis.
2025: Avacopan (TAVNEOS) remained an important treatment option for adults with severe active GPA or MPA, alongside established remission-induction and maintenance therapies.
Ongoing clinical development: Emerging therapies, including depemokimab, benralizumab, BDB-001, and other investigational candidates, are being evaluated to expand treatment options and address unmet medical needs.
What is Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis?
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA-associated Vasculitis) is a group of rare autoimmune disorders characterized by inflammation of small blood vessels. The three main types are granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). These conditions can affect the kidneys, lungs, upper respiratory tract, skin, nerves, and other organs. Symptoms vary depending on the organs involved and may include fatigue, fever, shortness of breath, skin lesions, and kidney dysfunction. Treatment generally involves immunosuppressive agents, glucocorticoids, biologics, and targeted therapies to induce and maintain remission.
ANCA-associated Vasculitis Epidemiology Segmentation
The ANCA-associated Vasculitis epidemiology section provides insights into the historical and current patient pool and forecasted trends across the leading markets. The report covers the study period 2022–2036, segmented into:
Total Diagnosed Prevalent Cases of ANCA-associated Vasculitis
Type-specific Diagnosed Prevalent Cases of ANCA-associated Vasculitis
Severity-specific Diagnosed Prevalent Cases of ANCA-associated Vasculitis
Diagnosed Prevalent Cases by Organ Involvement
Diagnosed Prevalent Cases by Antibody Type
Total Treated Cases of ANCA-associated Vasculitis
Scope of the ANCA-associated Vasculitis Market Report
Therapeutic Assessment: Current marketed and emerging therapies for ANCA-associated Vasculitis.
Market Dynamics: Key market forecast assumptions, emerging therapies, and market outlook.
Key Companies: GlaxoSmithKline, CSL, Amgen, NS Pharma, Novartis, NovelMed Therapeutics, and others.
Key Therapies: Avacopan (TAVNEOS), mepolizumab (NUCALA), benralizumab (FASENRA), depemokimab, BDB-001, iptacopan, NM8074, sparsentan, povetacicept, and others.
Competitive Intelligence Analysis: SWOT analysis, conjoint analysis, and competitive landscape assessment.
Unmet Needs and Market Access: Key opinion leader insights, analyst perspectives, treatment accessibility, pricing, and reimbursement.
To know more about ANCA-associated Vasculitis companies working in the treatment market, visit @ ANCA-associated Vasculitis Clinical Trials and Therapeutic Assessment
Table of Contents
ANCA-associated Vasculitis Market Report Introduction
Executive Summary for ANCA-associated Vasculitis
Key Events and Upcoming Catalysts
ANCA-associated Vasculitis Market Overview at a Glance
ANCA-associated Vasculitis Background and Overview
ANCA-associated Vasculitis Epidemiology and Patient Population
Country-Specific Patient Population of ANCA-associated Vasculitis
ANCA-associated Vasculitis Current Treatment and Medical Practices
ANCA-associated Vasculitis Patient Journey
ANCA-associated Vasculitis Marketed Therapies
ANCA-associated Vasculitis Emerging Therapies
ANCA-associated Vasculitis Market Outlook
Country-Wise ANCA-associated Vasculitis Market Analysis (2022–2036)
ANCA-associated Vasculitis Drug Uptake and Market Share
ANCA-associated Vasculitis Market Access and Reimbursement
ANCA-associated Vasculitis Market Drivers
ANCA-associated Vasculitis Market Barriers
ANCA-associated Vasculitis SWOT and Conjoint Analysis
ANCA-associated Vasculitis Report Methodology
DelveInsight Capabilities
Disclaimer
About DelveInsight
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in the life sciences and healthcare industries. Founded in 2014, the company provides comprehensive market intelligence, epidemiology, and insights across pharmaceuticals, biotechnology, medical devices, and emerging therapies. DelveInsight helps healthcare organizations make informed strategic decisions through data-driven research and industry expertise.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kirti Sharma
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting
The post Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapies | DelveInsight first appeared on PressReleaseCC.
